MiMedx (MDXG) Group and Vaporox jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the agreement, MIMEDX has made an investment in Vaporox and the Company has certain exclusivity rights related to potential acquisition discussions. “We are thrilled to continue delivering on our strategic goal of greater portfolio diversification through this collaboration with Vaporox,” commented Joseph Capper, MIMEDX Chief Executive Officer. “Together with our leading placental allografts, VHT will offer clinicians across numerous care settings another proven option to treat chronic, hard-to-heal wounds. We view this as a highly complementary addition that will help us grow in this important setting, where patients with difficult wounds often begin their recovery.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG:
- Video: Why Organogenesis And MiMedx Are Sinking Today
- MiMedx comments on proposed Medicare reimbursement rule changes
- Northland sees ‘key positive’ for MiMedx in CMS rule proposal
- Organogenesis selloff on CMS proposal ‘may be incorrect,’ says BTIG
- Organogenesis, MiMedx fall after CMS rule to cut skin substitutes spending